Evidence map›Paper›PMID 30957257›Full record

ArticleStatistics in medicine2019

Prioritized concordance index for hierarchical survival outcomes.

Li C Cheung, Qing Pan, Noorie Hyun, Hormuzd A Katki

Open access · greenAbstract read
In one paragraph

Article in Statistics in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Li C CheungDivision of Cancer Epidemiology and Genetics, NIH National Cancer Institute, Rockville, MD.ORCID 0000-0003-1625-4331
Qing PanDepartment of Statistics, The George Washington University, Washington, DC.
Noorie HyunInstitute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.
Hormuzd A KatkiDivision of Cancer Epidemiology and Genetics, NIH National Cancer Institute, Rockville, MD.ORCID 0000-0003-2002-0095
National Cancer Institute · USGeorge Washington University · USMedical College of Wisconsin · US

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

We propose an extension of Harrell's concordance (C) index to evaluate the prognostic utility of biomarkers for diseases with multiple measurable outcomes that can be prioritized. Our prioritized concordance index measures the probability that, given a random subject pair, the subject with the worst disease status as of a time τ has the higher predicted risk. Our prioritized concordance index uses the same approach as the win ratio, by basing generalized pairwise comparisons on the most severe or clinically important comparable outcome. We use an inverse probability weighting technique to correct for study-specific censoring. Asymptotic properties are derived using U-statistic properties. We apply the prioritized concordance index to two types of disease processes with a rare primary outcome and a more common secondary outcome. Our simulation studies show that when a predictor is predictive of both outcomes, the new concordance index can gain efficiency and power in identifying true prognostic variables compared to using the primary outcome alone. Using the prioritized concordance index, we examine whether novel clinical measures can be useful in predicting risk of type II diabetes in patients with impaired glucose resistance whose disease status can also regress to normal glucose resistance. We also examine the discrimination ability of four published risk models among ever smokers at risk of lung cancer incidence and subsequent death.

Indexed as

Models, StatisticalPrognosisBiomarkersComputer SimulationHumansProbabilityRisk AssessmentSurvivalBiomarkersarea under the receiver operating curveevaluating predictionsillness-death disease processprogressive/regressive disease processU-statistics

Identifiers

PMID30957257
PMCPMC6800570
OpenAlexW2936017671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.